<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ATP-sensitive K+ (K(ATP)) channels play many important roles in cellular functions, including control of membrane excitability of skeletal muscle and neurons, K+ recycling in renal epithelia, cytoprotection in <z:mp ids='MP_0004120'>cardiac ischemia</z:mp>, and insulin secretion from pancreatic beta-cells </plain></SENT>
<SENT sid="1" pm="."><plain>K(ATP) channels are composed of pore-forming inwardly rectifying <z:chebi fb="120" ids="26216">potassium</z:chebi> channel (Kir6.2 or Kir6.1) subunits and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> receptor (SUR1, SUR2A, or SUR2B) subunits </plain></SENT>
<SENT sid="2" pm="."><plain>Kir6.2 or Kir6.1 subunits conjoined with a SUR subunit constitute the various tissue-specific K(ATP) channels with distinct pharmacological properties </plain></SENT>
<SENT sid="3" pm="."><plain>Both <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and non-<z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> are used in treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>While the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> receptor (SUR) is the target molecule of <z:hpo ids='HP_0000001'>all</z:hpo> of these <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi>, the binding sites differ according to the moiety containing in the agent, and alter the pharmachological properties </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:hpo ids='HP_0011010'>chronic</z:hpo> exposure of pancreatic beta-cells to the various agents affects the agent-specific sensitivities differently </plain></SENT>
<SENT sid="6" pm="."><plain>Here we distinguish differences in pharmacological profile among the various <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> that reflect their chemical composition </plain></SENT>
<SENT sid="7" pm="."><plain>We also suggest possible risk in the use of certain <z:chebi fb="0" ids="35526">hypoglycemic agents</z:chebi> in patients with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
</text></document>